Comparative Pharmacology
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus INVEGA SUSTENNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPIPRAZOLE HYDROCHLORIDE versus INVEGA SUSTENNA.
DAPIPRAZOLE HYDROCHLORIDE vs INVEGA SUSTENNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dapiprazole is a selective alpha-1 adrenergic receptor antagonist. It blocks alpha-1 receptors on the smooth muscle of the iris dilator muscle, causing miosis (pupil constriction).
Paliperidone is an atypical antipsychotic that acts primarily as a central dopamine type 2 (D2) receptor antagonist and serotonin type 2A (5-HT2A) receptor antagonist. It also blocks α1- and α2-adrenergic receptors and H1 histamine receptors.
5 mg orally once daily, titrated as needed up to 10 mg once daily.
Initiate with 234 mg intramuscular injection on day 1, then 156 mg on day 8, both deltoid. Maintenance: 117 mg monthly (range 39-234 mg) via deltoid or gluteal injection. Dosing based on paliperidone palmitate.
None Documented
None Documented
Terminal elimination half-life is 78 hours; requires dose adjustment in renal impairment
Terminal elimination half-life ranges from 25 to 49 days (mean ~38 days) for deltoid injection and 30 to 50 days (mean ~45 days) for gluteal injection, supporting monthly dosing.
Primarily renal (80-90% as unchanged drug and metabolites); fecal (10-20%)
Renal: approximately 59-80% as unchanged drug and metabolites, with about 1% unchanged; biliary/fecal: approximately 20-41% primarily as metabolites.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic